FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Related Keywords

Paulag Oconnor , ,International Primary Central Nervous System Lymphoma ,Collaborative Group ,International Workshop On Chronic Lymphocytic Leukemia ,International Working Group ,Nurix Therapeutics Inc ,Nurix Therapeutics ,International Workshop ,Chronic Lymphocytic Leukemia ,Lugano Classification ,